ECOS: Efficacy of Chronoterapy in Oral Surgery

Sponsor
Universidad Complutense de Madrid (Other)
Overall Status
Completed
CT.gov ID
NCT05126264
Collaborator
McGill University (Other)
10
1
2
1.8
5.6

Study Details

Study Description

Brief Summary

Lower third molar extraction is one of the most common treatments in oral surgery practice. It is a treatment with inherent complications such as postoperative pain, swelling or trismus. In order to minimize disconfort after extraction, analgesic and anti-inflammatory medication is prescribed. Recently, it is seen that circadian rhythm may play an important role on drugs metabolism, modulating its effect depending on the moment of administration. The aim of the study is to analyze if dosage modification of a Non Steroideal Anti-Inflammatory (ibuprofen) affects on postoperative pain, swelling and open mouth limitation comparing to the normal dosage.

Condition or Disease Intervention/Treatment Phase
  • Drug: Ibuprofen 400 mg
  • Drug: Ibuprofen 400 mg
N/A

Detailed Description

A randomized crossover split-mouth clinical trial will be performed. After third molar extractions, patients will be prescribed ramdomly in one side wit the normal medication dosage while the contralateral side will be prescribed a modified dosage. Moreover, a blood sample will be obtained to analize the inflammatory profile.

Study Design

Study Type:
Interventional
Actual Enrollment :
10 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Intervention Model Description:
Split-mouth designSplit-mouth design
Masking:
Double (Participant, Care Provider)
Primary Purpose:
Treatment
Official Title:
Efficacy of the Dosage of a Non-steroidal Anti-inflammatory (Ibuprofen) on Inflammation and Postoperative Pain After Lower Third Molar Surgery.
Actual Study Start Date :
Dec 10, 2021
Actual Primary Completion Date :
Dec 10, 2021
Actual Study Completion Date :
Feb 2, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Modified dosage

Ibuprofen pill at morning and afternoon; Placebo at night

Drug: Ibuprofen 400 mg
morning and afternoon
Other Names:
  • Modified dosage
  • Active Comparator: Normal dosage

    Ibuprofen three times a day: morning, afternoon and night

    Drug: Ibuprofen 400 mg
    morning, afternoon and night
    Other Names:
  • Conventional dosage
  • Outcome Measures

    Primary Outcome Measures

    1. Post operative Pain [From the day of the surgical procedure to the seventh-day]

      Postoperative pain with visual analogue scale (VAS) from 0 (no pain) to 10 (maximum pain)

    Secondary Outcome Measures

    1. Swelling [Baseline and post operatory (day 1, day 3, day 7)]

      Distance from tragus to pogonion in milimiters

    Other Outcome Measures

    1. Trismus [Baseline and post operatory (day 1, day 3 and day 7)]

      Open mouth limitation in milimiters. Interincisal distance

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 35 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Age between 18 and 35 years old

    • Bilateral retained lower third molar

    Exclusion Criteria:
    • NSAID allergic

    • Contraindication for surgical removal of third molar

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Fabian Perez Gonzalez Madrid Spain 28040

    Sponsors and Collaborators

    • Universidad Complutense de Madrid
    • McGill University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Jesús Torres García Denche, Associate professor, Universidad Complutense de Madrid
    ClinicalTrials.gov Identifier:
    NCT05126264
    Other Study ID Numbers:
    • 2019-000736-25
    First Posted:
    Nov 18, 2021
    Last Update Posted:
    Feb 3, 2022
    Last Verified:
    Feb 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Keywords provided by Jesús Torres García Denche, Associate professor, Universidad Complutense de Madrid
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 3, 2022